New progress on diagnosis and treatment of acute cellular rejection after lung transplantation
10.3969/j.issn.1674-7445.2021.05.017
- VernacularTitle:肺移植术后急性细胞介导排斥反应的诊疗新进展
- Author:
Yu XU
1
;
Qiaoyan LIAN
;
Ao CHEN
;
Jianheng ZHANG
;
Xin XU
;
Bing WEI
;
Yuhang CAI
;
Danxia HUANG
;
Minting KUANG
;
Jianxing HE
;
Chunrong JU
Author Information
1. Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510012, China
- Publication Type:Research Article
- Keywords:
Lung transplantation;
Acute cellular rejection;
Cytotoxic T lymphocyte;
Human leukocyte antigen (HLA);
Major histocompatibility complex (MHC);
Histopathological examination;
Bronchoalveolar lavage fluid;
Vascular endothelial growth factor (VEGF)
- From:
Organ Transplantation
2021;12(5):614-
- CountryChina
- Language:Chinese
-
Abstract:
Acute cellular rejection (ACR) is a common complication after lung transplantation, which is mainly caused by the immune response of T lymphocytes recognizing the major histocompatibility complex on the cellular surface of grafts. It is currently considered as the main pattern of acute rejection. ACR is not only a direct cause of death of recipients, but also a high-risk factor for chronic rejection after lung transplantation. Nevertheless, it is a challenging task to deliver the diagnosis and treatment of ACR following lung transplantation. In this article, new progresses on the risk factors, pathogenesis, diagnosis and treatment of ACR in lung transplant recipients were summarized, aiming to improve the diagnostic and treatment efficiency of ACR and prolong the survival of recipients.
